HAWAII BIOTECH, INC. — Department of Health and Human Services SBIR Phase II: 105
HAWAII BIOTECH, INC. — SBIR Phase II award from Department of Health and Human Services.
Phase II SBIR prototype / development signal
- Phase II is where Department of Health and Human Services funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- At $2,997,218, this is a large obligation for typical SBIR Phase sizing — worth reviewing for scope breadth and teaming opportunity.
- Topic code 105 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $2,997,218
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- 105
- Solicitation
- PHS-2022-1
- NAICS
- —
- Place of performance
- HI
- Period
- —
Description
The contract supports the development of TLR4 agonist within an oil-in-water emulsion as a vaccine adjuvant. The adjuvant development activities are being conducted within the context of vaccines to protect against West Nile virus infection.